Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...
Add Yahoo as a preferred source to see more of our stories on Google. If prostate cancer is discovered early, the chances of recovery are often good. Axel Heimken/dpa Almost half of men falsely ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of ...
The media frenzy surrounding former President Joe Biden’s metastatic prostate cancer diagnosis last May didn’t faze one Lancaster resident. Doctors and politicians debated whether Biden and his ...
Nanostics has secured funding from Genome Canada and Genome Alberta to expedite the ClarityDX Prostate test integration into the standard of care for prostate cancer screening throughout the country.
Prostate cancer is one of the most frequently diagnosed cancers in men yet is often highly treatable when detected early. It originates in the prostate gland, located between the bladder and the penis ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene ...
A new blood test for prostate cancer that offers greater accuracy than prostate-specific antigen (PSA) has been put to the test by researchers at the University of East Anglia (UEA) in collaboration ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its market-leading Decipher Prostate Genomic Classifier is the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results